Label: information for the patient
Briviact 10 mg film-coated tablets
Briviact 25 mg film-coated tablets
Briviact 50 mg film-coated tablets
Briviact 75 mg film-coated tablets
Briviact 100 mg film-coated tablets
brivaracetam
Read this label carefully before starting to take this medicine, because
it contains important information for you.
What is Briviact
Briviact contains the active ingredient brivaracetam. It belongs to a group of medicines called “antiepileptics”. These medicines are used for the treatment of epilepsy.
What is Briviact used for
Do not take Briviact
Warnings and precautions
Consult your doctor or pharmacist before starting to take Briviact:
Children
Briviact is not recommended for children under 2 years old.
Taking Briviact with other medicines
Inform your doctor or pharmacist if you are taking, have taken recently or may need to take any other medicine.
In particular, inform your doctor if you are taking any of the following medicines, as you will need to adjust your Briviact dose:
Taking Briviact with alcohol
Pregnancy and breastfeeding
Women of childbearing ageshould discuss the use of contraceptives with their doctor.
Briviact is not recommended during pregnancy, as the effects of Briviact on pregnancy and the fetus are unknown.
Do not breastfeed your baby while taking Briviact, as Briviact is excreted in breast milk.
Do not stop treatment without consulting your doctor first. Stopping treatment may increase the number of your seizures and harm your baby.
Driving and operating machinery
Briviact contains lactose and sodium
Briviact film-coated tablets contain:
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again. Other forms of this medication may be more suitable for some patients, for example, children (if they cannot swallow whole tablets, for instance). Consult your doctor or pharmacist.
You will take Briviact along with other medications to treat epilepsy.
Dose
Your doctor will calculate the correct daily dose for you. Take the daily dose divided into two equal doses, approximately with 12 hours of difference.
Adolescents and children weighing 50 kg or more, and adults
Adolescents and children weighing between 20 kg and less than 50 kg
Children weighing between 10 kg and less than 20 kg
The recommended dose ranges from 0.5 mg to 2.5 mg per kilogram of body weight, twice a day. Your child's doctor may then decide to adjust the dose to find the best dose for your child.
Patients with liver problems
If you have liver problems:
How to take Briviact tablets
Duration of Briviact treatment
Briviact is a long-term treatment – continue taking Briviact until your doctor tells you to stop.
If you take more Briviact than you should
If you take more Briviact than you should, consult your doctor. You may feel dizzy and drowsy.
You may also experience some of the following symptoms: feeling unwell, feeling like you are spinning, difficulty maintaining balance, anxiety, feeling extremely tired, irritability, aggression, difficulty sleeping, depression, thoughts or attempts of self-harm or suicide.
If you forget to take Briviact
If you interrupt Briviact treatment
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may produce adverse effects, although not all people may experience them.
Very Frequent:may affect more than 1 in 10 patients.
Frequent:may affect up to 1 in 10 patients.
Rare:May affect up to 1 in 100 patients
Other Adverse Effects in Children
Frequent:may affect up to 1 in 10 patients.
-restlessness and hyperactivity (psychomotor hyperactivity)
Reporting Adverse Effects
If you experienceany type of adverse effect, consult your doctor or pharmacist, even if it is apossibleadverse effect that does not appear in this prospectus.You can also report them directlythrough thenational notification system included in theAppendix V.By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Briviact Composition
The other components are:
Core
Sodium croscarmellose, lactose monohydrate, beta-cyclodextrin, anhydrous lactose, magnesium stearate.
Tablet coating
Appearance of the product and contents of the pack
Briviact 10 mg are white to off-white, round, 6.5 mm diameter film-coated tablets, engraved with “u 10” on one side.
Briviact 25 mg are grey, oval-shaped, 8.9 mm x 5.0 mm film-coated tablets, engraved with “u 25” on one side.
Briviact 50 mg are yellow, oval-shaped, 11.7 mm x 6.6 mm film-coated tablets, engraved with “u 50” on one side.
Briviact 75 mg are purple, oval-shaped, 13.0 mm x 7.3 mm film-coated tablets, engraved with “u 75” on one side.
Briviact 100 mg are grey-green, oval-shaped, 14.5 mm x 8.1 mm film-coated tablets, engraved with “u 100” on one side.
Briviact tablets are packaged in blisters included in cartons containing either 14, 56, 14 x 1 or 100 x 1 film-coated tablets or in multiple packs containing 168 (3 packs of 56) film-coated tablets.
All packs are available in PVC/PCTFE-Aluminium blisters.
Not all pack sizes may be marketed.
Marketing authorisation holder and responsible person for manufacturing
Marketing authorisation holder
UCB Pharma, S.A., Allée de la Recherche 60, B-1070, Brussels, Belgium.
Responsible person for manufacturing
UCB Pharma, S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium.
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
België/Belgique/Belgien UCB Pharma SA/NV Tel/Tel: + 32 / (0)2 559 92 00 | Lietuva UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Suomija) | |
???????? ? ?? ?????????? ???? Te?.: + 359 (0) 2 962 30 49 | Luxembourg/Luxemburg UCB Pharma SA/NV Tél/Tel: + 32 / (0)2 559 92 00(Belgique/Belgien) | |
Ceská republika UCB s.r.o. Tel:+ 420221 773 411 | Magyarország UCB Magyarország Kft. Tel.: + 36-(1) 391 0060 | |
Danmark UCB Nordic A/S Tlf: + 45 / 32 46 24 00 | Malta Pharmasud Ltd. Tel: + 356 / 21 37 64 36 | |
Deutschland UCB Pharma GmbH Tel: + 49 /(0) 2173 48 4848 | Nederland UCB Pharma B.V. Tel.: + 31 / (0)76-573 11 40 | |
Eesti UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Soome) | Norge UCB Nordic A/S Tlf: +47/67 16 5880 | |
Ελλ?δα UCBΑ.Ε. Τηλ: + 30 / 2109974000 | Österreich UCB Pharma GmbH Tel: + 43-(0)1 291 80 00 | |
España UCB Pharma, S.A. Tel: + 34 / 91 570 34 44 | Polska UCB Pharma Sp. z o.o./VEDIM Sp. z o.o. Tel: + 48 22 696 99 20 | |
France UCB Pharma S.A. Tél: + 33 / (0)147 29 44 35 | Portugal UCB Pharma (Produtos Farmacêuticos), Lda Tel: + 351 / 21 302 5300 | |
Hrvatska Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46 | România UCB Pharma Romania S.R.L. Tel: + 40 21 300 29 04 | |
Ireland UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 | Slovenija Medis, d.o.o. Tel: + 386 1 589 69 00 | |
Ísland Vistor hf. Simi: + 354 535 7000 | Slovenská republika UCB s.r.o.,organizacná zložka Tel: + 421 (0) 2 5920 2020 | |
Italia UCB Pharma S.p.A. Tel: + 39 / 02 300 791 | Suomi/Finland UCB Pharma Oy Finland Puh/Tel: + 358 9 2514 4221 | |
Κ?προς Lifepharma (Z.A.M.) Ltd Τηλ: + 357 22 05 63 00 | Sverige UCB Nordic A/S Tel: + 46 / (0) 40 29 49 00 | |
Latvija UCB Pharma Oy Finland Tel: + 358 9 2514 4221 (Somija) | United Kingdom (Northern Ireland) UCB (Pharma) Ireland Ltd. Tel: + 353 / (0)1-46 37 395 |
Last update date of this leaflet:
Other sources of information
Further detailed information on this medicinal product is available on the website of the European Medicines Agency:http://www.ema.europa.eu
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.